TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
Co-inhibitory receptors (IRs) are molecules that protect host against autoimmune reactions and maintain peripheral self-tolerance, playing an essential role in maintaining immune homeostasis. In view of the substantial clinical progresses of negative immune checkpoint blockade in cancer treatment, t...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.911919/full |
| _version_ | 1818263414342942720 |
|---|---|
| author | Chenran Yue Sheng Gao Shuting Li Zhouhang Xing Hengrong Qian Ying Hu Wenqian Wang Chunyan Hua |
| author_facet | Chenran Yue Sheng Gao Shuting Li Zhouhang Xing Hengrong Qian Ying Hu Wenqian Wang Chunyan Hua |
| author_sort | Chenran Yue |
| collection | DOAJ |
| description | Co-inhibitory receptors (IRs) are molecules that protect host against autoimmune reactions and maintain peripheral self-tolerance, playing an essential role in maintaining immune homeostasis. In view of the substantial clinical progresses of negative immune checkpoint blockade in cancer treatment, the role of IRs in autoimmune diseases is also obvious. Several advances highlighted the substantial impacts of T cell immunoglobulin and ITIM domain (TIGIT), a novel IR, in autoimmunity. Blockade of TIGIT pathway exacerbates multiple autoimmune diseases, whereas enhancement of TIGIT function has been shown to alleviate autoimmune settings in mice. These data suggested that TIGIT pathway can be manipulated to achieve durable tolerance to treat autoimmune disorders. In this review, we provide an overview of characteristics of TIGIT and its role in autoimmunity. We then discuss recent approaches and future directions to leverage our knowledge of TIGIT as therapeutic target in autoimmune diseases. |
| first_indexed | 2024-12-12T19:18:38Z |
| format | Article |
| id | doaj.art-d10da550902e46639023d944b3d62cbb |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-12T19:18:38Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-d10da550902e46639023d944b3d62cbb2022-12-22T00:14:40ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-06-011310.3389/fimmu.2022.911919911919TIGIT as a Promising Therapeutic Target in Autoimmune DiseasesChenran Yue0Sheng Gao1Shuting Li2Zhouhang Xing3Hengrong Qian4Ying Hu5Wenqian Wang6Chunyan Hua7School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, ChinaLaboratory Animal Center, Wenzhou Medical University, Wenzhou, ChinaSchool of the Second Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, ChinaSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, ChinaSchool of the Second Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, ChinaSchool of the Second Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, ChinaDepartment of Surgery, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, ChinaSchool of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, ChinaCo-inhibitory receptors (IRs) are molecules that protect host against autoimmune reactions and maintain peripheral self-tolerance, playing an essential role in maintaining immune homeostasis. In view of the substantial clinical progresses of negative immune checkpoint blockade in cancer treatment, the role of IRs in autoimmune diseases is also obvious. Several advances highlighted the substantial impacts of T cell immunoglobulin and ITIM domain (TIGIT), a novel IR, in autoimmunity. Blockade of TIGIT pathway exacerbates multiple autoimmune diseases, whereas enhancement of TIGIT function has been shown to alleviate autoimmune settings in mice. These data suggested that TIGIT pathway can be manipulated to achieve durable tolerance to treat autoimmune disorders. In this review, we provide an overview of characteristics of TIGIT and its role in autoimmunity. We then discuss recent approaches and future directions to leverage our knowledge of TIGIT as therapeutic target in autoimmune diseases.https://www.frontiersin.org/articles/10.3389/fimmu.2022.911919/fullautoimmunityTIGITimmune regulationtherapeutic targetco-inhibitory receptors |
| spellingShingle | Chenran Yue Sheng Gao Shuting Li Zhouhang Xing Hengrong Qian Ying Hu Wenqian Wang Chunyan Hua TIGIT as a Promising Therapeutic Target in Autoimmune Diseases Frontiers in Immunology autoimmunity TIGIT immune regulation therapeutic target co-inhibitory receptors |
| title | TIGIT as a Promising Therapeutic Target in Autoimmune Diseases |
| title_full | TIGIT as a Promising Therapeutic Target in Autoimmune Diseases |
| title_fullStr | TIGIT as a Promising Therapeutic Target in Autoimmune Diseases |
| title_full_unstemmed | TIGIT as a Promising Therapeutic Target in Autoimmune Diseases |
| title_short | TIGIT as a Promising Therapeutic Target in Autoimmune Diseases |
| title_sort | tigit as a promising therapeutic target in autoimmune diseases |
| topic | autoimmunity TIGIT immune regulation therapeutic target co-inhibitory receptors |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.911919/full |
| work_keys_str_mv | AT chenranyue tigitasapromisingtherapeutictargetinautoimmunediseases AT shenggao tigitasapromisingtherapeutictargetinautoimmunediseases AT shutingli tigitasapromisingtherapeutictargetinautoimmunediseases AT zhouhangxing tigitasapromisingtherapeutictargetinautoimmunediseases AT hengrongqian tigitasapromisingtherapeutictargetinautoimmunediseases AT yinghu tigitasapromisingtherapeutictargetinautoimmunediseases AT wenqianwang tigitasapromisingtherapeutictargetinautoimmunediseases AT chunyanhua tigitasapromisingtherapeutictargetinautoimmunediseases |